ArticleOncology nursing forum2025
Consideration for Multigene Panel Testing Outside of Cancer-Specific Genetic Testing.
Article in Oncology nursing forum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the National Comprehensive Cancer Network (NCCN) guidelines for the care of patients with malignancies and capture the expected number of patients with pathogenic variants (PVs) linked to hereditary cancers. This research assessed how well the NCCN Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, version 3.2023, and Genetic/Familial High-Risk Assessment: Colorectal, version 2.2022, guidelines identify patients with cancer-related PVs. SAMPLE &
setting116 health records of patients aged 18 years or older who completed an 84-multigene cancer panel study in a hospital in the midwestern United States were reviewed. METHODS & VARIABLES: The hospital system's cancer risk assessment clinical database was used to acquire patient information and test results from patients with PVs. These data were evaluated against NCCN guidelines to determine whether testing guidelines were met.
resultsThere were 38 participants who met NCCN testing guidelines for hereditary breast cancer, 24 who met Lynch syndrome criteria, and 17 who had a single PV but did not meet any of the testing criteria. IMPLICATIONS FOR NURSING: This retrospective chart review verifies the need for multigene panel testing. There were 17 patients with PVs who did not meet NCCN guidelines for testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.